Pima County STEPs gives low-level drug offenders second chance
Pima County STEPs gives low level drug offenders second chance By Jasmine Ramirez | April 5, 2021 at 6:13 PM MST - Updated April 6 at 5:44 AM
TUCSON, Ariz. (KOLD News 13) - Pima County Superior Court is offering a second chance to some people brought before the court on low-level drug charges. The Supportive Treatment and Engagement Program, also known as STEPs, is for nonviolent individuals struggling with addiction and mental health issues. Those who qualify will receive substance-use treatment. The drug charge is dismissed after treatment is completed.
Presiding Judge Danelle Liwski said a person with a drug charge typically waits six months to a year to be sentenced but this program is a game changer.
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET | Source: BioAegis Therapeutics BioAegis Therapeutics Morristown, New Jersey, UNITED STATES
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported
that low levels of gelsolin are associated with severity and organ failure in COVID-19 patients, with the lowest pGSN levels seen in patients who subsequently died. BioAegis is currently conducting a Phase 2 clinical trial of recombinant human plasma gelsolin (rhu-pGSN) in severe COVID-19 patients to supplement gels